Associated Papers
Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma.
Wei Y et al.
Pathology, Research and Practice, 2026
Four decades of the RET gene: From discovery to tumor-agnostic therapy.
Takahashi M
Journal of the Formosan Medical Association = Taiwan Yi Zhi, 2025
Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials.
Gil-Bernabé S et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 2025
Treatment of non-small cell lung cancer with RET rearrangements.
Hoe HJ et al.
Cancer, 2025
Mechanisms of resistance to RET-directed therapies.
Clifton-Bligh RJ
Endocrine-related Cancer, 2025
Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma.
Gigliotti BJ et al.
Molecular and Cellular Endocrinology, 2024
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.
Chen MF et al.
Drugs, 2024
Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".
Spitaleri G et al.
Cancers, 2024
Medullary Thyroid Cancer: Molecular Drivers and Immune Cellular Milieu of the Tumour Microenvironment-Implications for Systemic Treatment.
Papachristos AJ et al.
Cancers, 2024
Developing Dynamic Structure-Based Pharmacophore and ML-Trained QSAR Models for the Discovery of Novel Resistance-Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI Analysis.
Sayyah E et al.
Chemmedchem, 2024
RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.
Hamidi S et al.
Annales D'endocrinologie, 2024
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.
Sahakian N et al.
Cancers, 2023
RET-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity.
Desilets A et al.
Cancers, 2023
Progress and challenges in RET-targeted cancer therapy.
Hu X et al.
Frontiers of Medicine, 2023
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
Servetto A et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2022
Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F et al.
Archives of Pharmacal Research, 2022
Updates on therapy for medullary thyroid cancer in 2021.
Puerto M et al.
Annales D'endocrinologie, 2022
Non-small-cell lung cancer: how to manage RET-positive disease.
Andrini E et al.
Drugs in Context, 2022
RET signaling pathway and RET inhibitors in human cancer.
Regua AT et al.
Frontiers in Oncology, 2022
Precision oncology for RET-related tumors.
Verrienti A et al.
Frontiers in Oncology, 2022
Precision therapy for RET-altered cancers with RET inhibitors.
Thein KZ et al.
Trends in Cancer, 2021
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Saha D et al.
Journal of Medicinal Chemistry, 2021
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.
Moccia M et al.
Scientific Reports, 2021
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib.
Shen T et al.
Npj Precision Oncology, 2021
Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
Terzyan SS et al.
The Journal of Biological Chemistry, 2019
Drug resistance profiles of mutations in the RET kinase domain.
Liu X et al.
British Journal of Pharmacology, 2018
The role of the ret proto-oncogene in human disease.
Takahashi M
Nagoya Journal of Medical Science, 1997